Sam Whitehead/KFF Health NewsPrEP is a crucial tool in the fight against the ongoing HIV epidemic and, when taken as prescribed, is highly effective at preventing infection from sexual contact or injection drug use.
But more than a decade after the first PrEP drug was approved for the US market, one of the groups that would benefit most from the medications isn’t taking them: Black women, whose gender identity align with their sex assigned at birth.
Read the full story at KFF Health News.
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.